TD Asset Management Inc Purchases New Position in Metsera Inc. (NASDAQ:MTSR)

Key Points

• TD Asset Management Inc has acquired 76,824 shares of Metsera Inc., valued at approximately $2,091,000, increasing its ownership to 0.07% of the company.
• Several large investors, including Alphabet Inc. and Massachusetts Financial Services Co., have also made significant new investments in Metsera during the first quarter.
• Research analysts have set a new average price target of $55.00 for Metsera, with some analysts giving it a "buy" rating and targets as high as $65.00.

TD Asset Management Inc bought a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 76,824 shares of the company's stock, valued at approximately $2,091,000. TD Asset Management Inc owned about 0.07% of Metsera as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MTSR. New York State Common Retirement Fund acquired a new stake in Metsera during the 1st quarter worth $131,000. Bank of New York Mellon Corp purchased a new position in shares of Metsera during the 1st quarter worth $884,000. Jennison Associates LLC purchased a new position in shares of Metsera during the 1st quarter worth $9,679,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Metsera during the 1st quarter worth $13,111,000. Finally, Alphabet Inc. purchased a new position in shares of Metsera during the 1st quarter worth $135,059,000.

Metsera Price Performance

NASDAQ:MTSR traded down $1.09 on Tuesday, reaching $33.35. 1,318,543 shares of the company's stock were exchanged, compared to its average volume of 959,940. The business has a fifty day simple moving average of $32.74. Metsera Inc. has a 52-week low of $12.30 and a 52-week high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wells Fargo & Company assumed coverage on Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target on the stock. Guggenheim boosted their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera currently has an average rating of "Buy" and a consensus target price of $55.00.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.